HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Karyopharm Therapeutics (NASDAQ:KPTI) and maintained a price target of $8.
June 03, 2024 | 10:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Karyopharm Therapeutics and maintained a price target of $8.
The reiteration of a Buy rating and the maintenance of a price target at $8 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100